| Targeted Investigation of Microbiome Elimination (NCT05177328) | National Institute of Allergy and Infectious Diseases (NIAID) | 2022-07-18 |
| A Study to Learn About Abrocitinib Tablets in People With Atopic Dermatitis in India (NCT05375929) | Pfizer | 2022-07-16 |
| A Phase III Study of Jaktinib in Adults With Moderate and Severe Atopic Dermatitis (NCT05526222) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2022-07-14 |
| Study to Assess the Efficacy and Safety of Orismilast in Atopic Dermatitis (ADESOS) (NCT05469464) | UNION therapeutics | 2022-07-11 |
| Tencel vs. Standard Cotton Therapeutic Garments as an Adjunct Treatment for Moderate to Severe Atopic Dermatitis in Children (NCT03843437) | Johns Hopkins University | 2022-07-01 |
| A Study to Assess Subcutaneous Lirentelimab (AK002) in Atopic Dermatitis (NCT05155085) | Allakos Inc. | 2022-06-27 |
| Effects of Tralokinumab in the Skin: an Immunologic and Molecular Investigation (NCT05378698) | University of Zurich | 2022-06-15 |
| An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis (NCT05399368) | RAPT Therapeutics, Inc. | 2022-06-07 |
| A Long-Term Extension Trial in Participants With Atopic Dermatitis Who Participated in Previous EDP1815 Trials (NCT05439941) | Evelo Biosciences, Inc. | 2022-06-06 |
| Treatment and Medical Care of Patients With Moderate-to-severe Atopic Dermatitis - TREATswitzerland (NCT05819463) | Swiss Society of Dermatology and Venereology | 2022-06-02 |
| An Observational Study of Upadacitinib to Assess Change in Disease Activity in Canadian Adult Participants With Moderate-to-Severe Atopic Dermatitis Who Are Inadequate Responders To or Discontinuing Dupilumab (NCT05394792) | AbbVie | 2022-06-01 |
| A Study of TQH2722 Injection to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Immunogenicity in Healthy Adult Subjects (NCT05409326) | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | 2022-06-01 |
| A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE) (NCT05398445) | Amgen | 2022-05-31 |
| Evaluation of an Adapted Formula on Atopic Dermatitis. (NCT05318300) | United Pharmaceuticals | 2022-05-24 |
| A Multi-omics Disease Signature Trial in Adult Patients With Moderate to Severe AD (NCT05470114) | LEO Pharma | 2022-05-19 |
| Study of ATI-1777 in Patients 12 to 65 Years Old With Mild to Severe Atopic Dermatitis (NCT05432596) | Aclaris Therapeutics, Inc. | 2022-05-11 |
| Social Media Follow-up Nursing for Atopic Dermatitis (NCT07142993) | The First Hospital of Hebei Medical University | 2022-05-01 |
| A Study of Topical BX005-A in Subjects With Moderate to Severe Atopic Dermatitis (NCT05240300) | BiomX, Inc. | 2022-05-01 |
| Skin Tracker: A Mobile Health App to Monitor Skin Disease Activity and Treatment Use (NCT04404075) | University of California, San Francisco | 2022-04-25 |
| A Study of CM310 in Patients With Moderate-to-Severe Atopic Dermatitis (NCT05265923) | Keymed Biosciences Co.Ltd | 2022-04-22 |
| Comparison of LimpiAD Cream 2.5% Plus Versus Its Vehicle and and a Basic Emollient in Patients With Atopic Dermatitis (NCT05984420) | Aileens Pharma SRL | 2022-04-21 |
| A Study to Learn About the Study Medicine (CIBINQO) in People With Atopic Dermatitis. (NCT05387980) | Pfizer | 2022-04-19 |
| Dupixent and Narrowband UVB for Atopic Dermatitis (NCT05285839) | Psoriasis Treatment Center of Central New Jersey | 2022-04-19 |
| A Study of Orally Administered IPG7236 in Healthy Adult Participants (NCT05288543) | Nanjing Immunophage Biotech Co., Ltd | 2022-04-07 |
| Bioavailability and Tolerability of Fexofenadine Hydrochloride Topical Lotion 1% (NCT05461456) | OrchestratePharma GmbH | 2022-04-01 |
| Atopic Dermatitis: Sub-Saharan Africa vs. Central Europe (NCT05363904) | University of Zurich | 2022-03-30 |
| Long-term Follow-up Study to Evaluate the Safety and Explore the Efficacy of Multiple Doses of FURESTEM-AD Inj (NCT04730024) | Kang Stem Biotech Co., Ltd. | 2022-03-27 |
| Phase 2b Study of ASLAN004 in Adults With Moderate-to-Severe Atopic Dermatitis (NCT05158023) | ASLAN Pharmaceuticals | 2022-03-16 |
| Efficacy and Safety of Blue Cap for the Treatment of Atopic Dermatitis in Children (NCT06361992) | Catalysis SL | 2022-03-15 |
| A Single-ascending Dose (Part A) and Repeat-dose (Part B) Study to Investigate the Safety, Pharmacokinetics and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B) (NCT05277571) | UCB Biopharma SRL | 2022-03-07 |
| SAD/MAD Safety and PK Study of RBN-3143 in Healthy and Atopic Dermatitis Subjects (NCT05215808) | Ribon Therapeutics, Inc. | 2022-03-07 |
| Study on the Influence of Climatic and Environmental Factors on Respiratory Diseases in Sanya, Hainan Province, China. (NCT05330637) | Shanghai Jiao Tong University School of Medicine | 2022-03-03 |
| Dupilmuab for Atopic Dermatitis Monitored With Noninvasive Imaging. (NCT05265234) | OptiSkin Medical | 2022-03-01 |
| Use of a Mobile Health App in Managing Pediatric Atopic Dermatitis (NCT06412094) | Avanta Trading Ltd. | 2022-03-01 |
| Skin Care Strategies for Neonatal Jaundice Phototherapy to Prevent Atopic Dermatitis in Moderate and Severe Infants (NCT05178433) | Shanghai First Maternity and Infant Hospital | 2022-02-01 |
| A Study Investigating the Effect of EDP1815 in the Treatment of Mild, Moderate and Severe Atopic Dermatitis (NCT05121480) | Evelo Biosciences, Inc. | 2022-01-31 |
| A Study of LNK01001 Capsule in Patients With Moderate to Severe Atopic Dermatitis (NCT06085521) | Lynk Pharmaceuticals Co., Ltd | 2022-01-26 |
| UVB-induced Treg Cells Exert Antigen-specific Suppression Through LAG-3 (NCT05636839) | National Taiwan University Hospital | 2022-01-25 |
| A Clinical Study in Healthy Subjects to Evaluate 9MW1911 Injection (NCT05170243) | Mabwell (Shanghai) Bioscience Co., Ltd. | 2022-01-21 |
| Efficacy and Safety of Tralokinumab Administered by an Autoinjector in Adults and Adolescents With Moderate to Severe Atopic Dermatitis (INJECZTRA) (NCT05194540) | LEO Pharma | 2022-01-13 |
| Immunomodulation by OM-85 (Broncho-Vaxom) in Early AD (NCT05222516) | OM Pharma SA | 2021-12-20 |
| Study of Ruxolitinib Cream in Children With Atopic Dermatitis (NCT05034822) | Incyte Corporation | 2021-12-16 |
| Real-world Experience on the Use of Upadacitinib in the Treatment of Moderate-severe Adult Atopic Dermatitis (ERUDA) (NCT05989932) | Societa Italiana di Dermatologia Medica, Chirurgica, Estetica e di Malattie Sessualmente Trasmesse | 2021-12-15 |
| An Evaluation of 9MW1911 Injection in Healthy Subjects (NCT05803902) | Mabwell (Shanghai) Bioscience Co., Ltd. | 2021-12-15 |
| Study Testing Response Effect of KY1005 Against Moderate-to-Severe Atopic Dermatitis, The STREAM-AD Study (NCT05131477) | Kymab Limited | 2021-12-13 |
| Efficacy and Safety of LEO 152020 Tablets for the Treatment of Adults With Moderate to Severe Atopic Dermatitis (NCT05117060) | JW Pharmaceutical | 2021-12-13 |
| Scratching Validation Study (NCT05137093) | Philips Clinical & Medical Affairs Global | 2021-12-10 |
| Creation of a Shared Medical Decision-making Tool for Atopic Dermatitis (NCT05090982) | Assistance Publique - Hôpitaux de Paris | 2021-12-01 |
| Evaluation of the Effectiveness and Safety of Immunosuppressive and Biological Therapy of Atopic Dermatitis in Childhood (NCT04895423) | National Medical Research Center for Children's Health, Russian Federation | 2021-11-25 |
| A Study to Assess Real-World Use, Safety, and Effectiveness of Oral Upadacitinib in Adult and Adolescent (>=12 Years Old) Participants With Atopic Dermatitis (NCT05081557) | AbbVie | 2021-11-17 |
| Maximal Use Study of Tapinarof Cream, 1% in Pediatric Subjects With Extensive Atopic Dermatitis (NCT05186805) | Organon and Co | 2021-11-15 |
| Ruxolitinib Cream in Participants With Facial and/or Neck Atopic Dermatitis Involvement (NCT05127421) | Incyte Corporation | 2021-11-10 |
| A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of AK120 in Subjects With Atopic Dermatitis (NCT06035354) | Akeso | 2021-11-03 |
| A Trial to Evaluate Pharmacokinetics, Immunogenicity, Safety, and Tolerability of LEO 138559 in Healthy Japanese Subjects (NCT05099133) | LEO Pharma | 2021-11-03 |
| A Clinical Trial to Evaluate the Safety and Efficacy of a Moisturizer Body Lotion in Adults of Atopic Dermatitis. (NCT05062213) | Johnson & Johnson Consumer Inc. (J&JCI) | 2021-11-01 |
| Exploratory Study to Evaluate the Application of NLAC Cream in Adults With Atopic Dermatitis (NCT05092464) | Microbio Co Ltd | 2021-10-31 |
| Long Term Extension Study of Tapinarof Cream, 1% for Subjects With Atopic Dermatitis (NCT05142774) | Organon and Co | 2021-10-28 |
| Safety and Tolerability of BSI-045B in Healthy Adult Subjects and Patients With Atopic Dermatitis (NCT05114889) | Biosion, Inc. | 2021-10-25 |
| The Role of Genetic Factors in the Development of Atopic Dermatitis in the Kazakh Population (NCT05090631) | Asfendiyarov Kazakh National Medical University | 2021-10-23 |
| The Epidemiology, Management and Comorbidities in Alopecia Areata in Czech Republic (NCT05098600) | Faculty Hospital Kralovske Vinohrady | 2021-10-15 |
| Electrochemistry Measurement of Skin Hydration Parameters (NCT05071456) | Assistance Publique - Hôpitaux de Paris | 2021-10-15 |
| Safety, Pharmacokinetics and Efficacy of FMX114 Versus Vehicle in Adults With Atopic Dermatitis (NCT04927572) | Vyne Therapeutics Inc. | 2021-10-13 |
| A Single-center, Randomized, Double-blinded, Placebo-controlled, Phase 1 Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of NCP112 (NCT05638165) | NovaCell Technology Inc. | 2021-10-13 |
| The Purpose of the Study is to Evaluate the Effect of Ruxolitinib Cream on Itch in Participants With Atopic Dermatitis (NCT04839380) | Incyte Corporation | 2021-10-12 |
| Study the Safety and Efficacy of DBI-001 Gel Versus Aqueous Gel (NCT05253755) | DermBiont, Inc. | 2021-10-06 |
| Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis (NCT05048056) | Akesobio Australia Pty Ltd | 2021-09-30 |
| A Study to Evaluate Adverse Events and Change in Disease State of Oral Upadacitinib in Adolescent Participants Ages 12 to <18 Years Old Diagnosed With Atopic Dermatitis (AD) (NCT05029895) | AbbVie | 2021-09-29 |
| BROadband vs Narrowband photoTherapy for Eczema Trial Nested in the CACTI Cohort (NCT04818138) | Women's College Hospital | 2021-09-27 |
| Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults (DMVT-505-3102) (NCT05032859) | Organon and Co | 2021-09-23 |
| Skin Responses and T Cell Immunology After House Dust Mite Exposure in Sensitized Atopic Dermatitis Patients (NCT05019209) | Fraunhofer-Institute of Toxicology and Experimental Medicine | 2021-09-10 |
| Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis (NCT05018806) | Sanofi | 2021-09-09 |
| Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults (NCT05014568) | Organon and Co | 2021-09-01 |
| Frequency of Palpebral Involvement in Adult With Atopic Dermatitis (NCT04826744) | University Hospital, Lille | 2021-09-01 |
| Evaluation of the Efficacy of Topialyse Baume barrière on Atopic Dermatis (NCT05006300) | SVR Group | 2021-09-01 |
| Phase 2a Study of the Safety, Tolerability, and Pharmacokinetics of Topically Administered PRN473 (SAR444727) in Patients With Mild to Moderate Atopic Dermatitis (NCT04992546) | Principia Biopharma, a Sanofi Company | 2021-08-13 |
| Metabolic Profiling of Immune Responses in Immune-mediated Diseases (NCT04864886) | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-08-10 |
| Replication of the Heads Up Atopic Dermatitis Trial With Registry Data (NCT06937788) | Technische Universität Dresden | 2021-08-02 |
| A Clinical Trial to Evaluate the Safety and Efficacy of a Moisturizer Body Lotion and a Lip Moisturizer in Adults of Atopic Dermatitis. (NCT04950374) | Johnson & Johnson Consumer Inc. (J&JCI) | 2021-07-26 |
| A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3) (NCT04921969) | Incyte Corporation | 2021-07-19 |
| An Evaluation of LEO 138559 in Adults With Moderate to Severe Atopic Dermatitis. (NCT04922021) | LEO Pharma | 2021-07-14 |
| Characterization of Chronic Hand Eczema (NCT05026554) | Dr. Robert Bissonnette | 2021-06-30 |
| Seal, Stopping Eczema and Allergy Study (NCT03742414) | Kari Nadeau, MD, PhD | 2021-06-30 |
| The Incidence of Venous Thromboembolism in Atopic Dermatitis (NCT04969653) | Momentum Data | 2021-06-21 |
| Continued Safety Evaluation of FB-401 in Children, Adolescents and Adults (2 Years and Older) With Mild to Moderate Atopic Dermatitis Previously Enrolled in the FB401-01 Study (NCT04936113) | Forte Biosciences, Inc. | 2021-06-02 |
| Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Application of Topical BioLexa in Adult Healthy Subjects and Patients With Mild to Moderate Atopic Dermatitis (NCT04544943) | Hoth Therapeutics, Inc. | 2021-05-17 |
| Evaluate Efficacy and Safety of Oral SHR0302 in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis (NCT04875169) | Reistone Biopharma Company Limited | 2021-04-30 |
| A Study to Assess the Efficacy and Safety of CMK389 in Patients With Moderate to Severe Atopic Dermatitis. (NCT04836858) | Novartis Pharmaceuticals | 2021-04-20 |
| The Effect of Isosorbide Diesters Based Moisturizer on Skin Health (NCT04831892) | Integrative Skin Science and Research | 2021-04-12 |
| Relationships Among Inflammation, Physical and Mental Health in Subjects With Chronic Inflammatory Physical Diseases. (NCT05125458) | University of Campania Luigi Vanvitelli | 2021-04-01 |
| MH004 Topical Cream in Healthy Adult Volunteers and Participants With Atopic Dermatitis or Rheumatoid Arthritis (NCT04815148) | Minghui Pharmaceutical Pty Ltd | 2021-04-01 |
| Observational Study to Evaluate the Actual Use of Elidel® in Chinese Patients With Mild to Moderate Atopic Dermatitis (NCT04976868) | Mylan Inc. | 2021-03-18 |
| Systems Biology of Early Atopy (NCT04798079) | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-03-18 |
| Comparison of LimpiAD Cream 2.5% Plus Versus Vehicle and an Emollient in Patients With Atopic Dermatitis (NCT05971355) | Aileens Pharma SRL | 2021-03-10 |
| Observational Study of Conjunctivitis in the Setting of DUPIXENT® Treatment for Atopic Dermatitis (NCT04287608) | Regeneron Pharmaceuticals | 2021-03-10 |
| The Role Of Neutrophil Proteases As Global Regulators Of Il-1 Family Cytokine Activity In Skin Disorders (NCT04750161) | St. James's Hospital, Ireland | 2021-03-02 |
| Efficacy Evaluation and Cutaneous Acceptability of the Lipikar Med Product on Subjects With Atopic Dermatitis (NCT05531188) | Cosmetique Active International | 2021-03-01 |
| Study in Healthy Participants and Participants With Moderate Atopic Dermatitis & Optionally, Moderate Psoriasis, and/or Mild Asthma (NCT04927195) | Evelo Biosciences, Inc. | 2021-02-23 |
| A Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS) (NCT04772885) | Kymera Therapeutics, Inc. | 2021-02-23 |
| A Prospective Sample Collection Study Using Non-invasive Methods to Investigate Biomarkers in AD Patients (NCT04699695) | DermTech | 2021-02-15 |
| Transcriptomic Landscape of T Lymphocytes of Atopic Dermatitis, Atopic Prurigo Nodularis (of Besnier) and Non-atopic Prurigo Nodularis (of Hyde) Using Single Cell RNA-sequencing (NCT04681300) | Assistance Publique - Hôpitaux de Paris | 2021-02-01 |